Antidiabetics Market By Product (Long Acting, Premixed Insulin, Intermediate Acting, Rapid Acting, Premixed Analog, Other Products) And Application (type I Diabetes And Type Ii Diabetes) - Global Industry Analysis And Forecast To 2025

Published On : July 2018 Pages : 190 Category: Pharmaceuticals Report Code : HC071105

Industry Outlook and Trend Analysis

Developing aged populace alongside raising diabetes commonness over the globe should drive the antidiabetics market. As per WHO, diabetes will be among the main sources of death by 2030 which represents a significant burden on the healthcare systems. These aspects will positively affect the worldwide use of insulin and additionally different antidiabetics including DPP-4 and GLP-1 over the gauge time frame. Leading sedentary lifestyle will add to expanding levels of obese populace over the world. Increasing consumption of tobacco, raised cholesterol levels and high blood pressure are major factors related with obesity and diabetes quickening the interest for insulin and other antidiabetic products in the upcoming years. Various campaigns for awareness and education programs composed by associations and diabetes societies to build awareness levels and provide information about diabetes control will drive industry extension.

Type Outlook and Trend Analysis

Insulin products represented the biggest share of the overall industry in 2016 and are foreseen to grow at around at a considerable CAGR over the coming years. Significant prevailing players are creating inventive products used to treat and keep the malady attributable to expanded burden of diabetes. Moreover, awareness campaign of Type II diabetes directed by Diabetes UK for viable administration of the ailment will support interest for insulin products.

Application Outlook and Trend Analysis

Type II diabetes segment was driving the income share in 2016 and should demonstrate a comparable pattern over the conjecture years. Existence of extensive patient pool experiencing type II diabetes attributable to leading unhealthy way of life combined with expanded protection from insulin will help interest for antidiabetic drugs in the upcoming years. On the other hand, Type I diabetes will hold a small share and is anticipated to witness huge development rate amid the gauge time frame.

Regional Outlook and Trend Analysis

The United States antidiabetics market represented biggest regional share in 2016 inferable from high predominance of diabetes in the nation. Increasing aged populace, expanding obesity, adopting unhealthy habits and absence of physical movement are the significant hazard factors for the expanding diabetes commonness adding to ascend sought after for insulin and other hostile to diabetic product over the coming couple of years. Germany antidiabetics market will encounter a hearty development over the conjecture time frame because of rising predominance of sort II diabetes which additionally results to expanded usage rate of antidiabetics in the nation.

Competitive Insights

The leading players in the market are Takeda Pharmaceutical Company, Pfizer, Sanofi, Novo Nordisk, Boehringer Ingelheim, AstraZeneca, Eli Lilly and Company, Merck & Co and Oramed Pharmaceuticals Inc. The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and share of the overall industry.

The Antidiabetics Market is segmented based on as follows-

By Product

  • Long Acting
  • Premixed Insulin
  • Intermediate Acting
  • Rapid Acting
  • Premixed Analog
  • Other Products

By Application

  • Type I Diabetes
  • Type II Diabetes

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Russia
    • Italy
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • India
    • Southeast Asia
    • Rest of Asia-Pacific
  • South America
    • Brazil
    • Argentina
    • Columbia
    • South Africa
    • Rest of South America
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Egypt
    • Nigeria
    • South Africa
    • Rest of MEA

Some of the key questions answered by the report are:

  • What was the market size in 2014 and forecast from 2015 to 2025?
  • What will be the industry market growth from 2015 to 2025?
  • What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
  • What are the major segments leading the market growth and why?
  • Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?

Market Classification

·         Antidiabetics Market, By Product, Estimates and Forecast, 2014-2025 ($Million)

·         Long Acting

·         Premixed Insulin

·         Intermediate Acting

·         Rapid Acting

·         Premixed Analog

·         Other Products

·         Antidiabetics Market, By Application, Estimates and Forecast, 2014-2025 ($Million)

·         Type I Diabetes

·         Type II Diabetes

·         Antidiabetics Market, By Region, Estimates and Forecast, 2014-2025 ($Million)

·         North America

§  North America Antidiabetics Market, By Country

o    U.S. Antidiabetics Market

o    Canada Antidiabetics Market

o    Mexico Antidiabetics Market

·         Europe

§  Europe Antidiabetics Market, By Country

o    Germany Antidiabetics Market

o    UK Antidiabetics Market

o    France Antidiabetics Market

o    Russia Antidiabetics Market

o    Italy Antidiabetics Market

o    Rest of Europe Antidiabetics Market

·         Asia-Pacific

§  Asia-Pacific Antidiabetics Market, By Country

o    China Antidiabetics Market

o    Japan Antidiabetics Market

o    South Korea Antidiabetics Market

o    India Antidiabetics Market

o    Southeast Asia Antidiabetics Market

o    Rest of Asia-Pacific Antidiabetics Market

·         South America

§  South America Antidiabetics Market

o    Brazil Antidiabetics Market

o    Argentina Antidiabetics Market

o    Columbia Antidiabetics Market

o    South Africa Antidiabetics Market

o    Rest of South America Antidiabetics Market

·         Middle East and Africa

§  Middle East and Africa Antidiabetics Market

o    Saudi Arabia Antidiabetics Market

o    UAE Antidiabetics Market

o    Egypt Antidiabetics Market

o    Nigeria Antidiabetics Market

o    South Africa Antidiabetics Market

o    Rest of MEA Antidiabetics Market

Table of Contents

1.       Introduction

1.1.     Report Description

2.       Executive Summary

2.1.     Key Highlights

3.       Market Overview

3.1.     Introduction

3.1.1.  Market Definition

3.1.2.  Market Segmentation

3.2.     Market Dynamics

3.2.1.  Drivers

3.2.2.  Restraints

3.2.3.  Opportunities

4.       Market Analysis by Regions

4.1.     North America (United States, Canada and Mexico)

4.1.1.  United States Market Status and Outlook (2014-2025)

4.1.2.  Canada Market Status and Outlook (2014-2025)

4.1.3.  Mexico Market Status and Outlook (2014-2025)

4.2.     Europe (Germany, France, UK, Russia, Italy and Rest of Europe)

4.2.1.  Germany Market Status and Outlook (2014-2025)

4.2.2.  France Market Status and Outlook (2014-2025)

4.2.3.  UK Market Status and Outlook (2014-2025)

4.2.4.  Russia Market Status and Outlook (2014-2025)

4.2.5.  Italy Market Status and Outlook (2014-2025)

4.2.6.  Rest of Europe Market Status and Outlook (2014-2025)

4.3.     Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)

4.3.1.  China Market Status and Outlook (2014-2025)

4.3.2.  Japan Market Status and Outlook (2014-2025)

4.3.3.  Korea Market Status and Outlook (2014-2025)

4.3.4.  India Market Status and Outlook (2014-2025)

4.3.5.  Southeast Asia Market Status and Outlook (2014-2025)

4.3.6.  Rest of Asia-Pacific Market Status and Outlook (2014-2025)

4.4.     South America (Brazil, Argentina, Columbia and Rest of South America)

4.4.1.  Brazil Market Status and Outlook (2014-2025)

4.4.2.  Argentina Market Status and Outlook (2014-2025)

4.4.3.  Columbia Market Status and Outlook (2014-2025)

4.4.4.  Rest of South America Market Status and Outlook (2014-2025)

4.5.     Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)

4.5.1.  Saudi Arabia Market Status and Outlook (2014-2025)

4.5.2.  United Arab Emirates Market Status and Outlook (2014-2025)

4.5.3.  Egypt Market Status and Outlook (2014-2025)

4.5.4.  Nigeria Market Status and Outlook (2014-2025)

4.5.5.  South Africa Market Status and Outlook (2014-2025)

4.5.6.  Turkey Market Status and Outlook (2014-2025)

4.5.7.  Rest of Middle East and Africa Market Status and Outlook (2014-2025)

5.       Antidiabetics Market, By Product

5.1.     Introduction

5.2.     Global Antidiabetics Revenue and Market Share by Product (2014-2018)

5.2.1.  Global Antidiabetics Revenue and Revenue Share by Product (2014-2018)

5.3.     Long Acting

5.3.1.  Global Long Acting Revenue and Growth Rate (2014-2018)

5.4.     Premixed Insulin

5.4.1.  Global Premixed Insulin Revenue and Growth Rate (2014-2018)

5.5.     Intermediate Acting

5.5.1.  Global Intermediate Acting Revenue and Growth Rate (2014-2018)

5.6.     Rapid Acting

5.6.1.  Global Rapid Acting Revenue and Growth Rate (2014-2018)

5.7.     Premixed Analog

5.7.1.  Global Premixed Analog Revenue and Growth Rate (2014-2018)

5.8.     Other Products

5.8.1.  Global Other Products Revenue and Growth Rate (2014-2018)

6.       Antidiabetics Market, By Application

6.1.     Introduction

6.2.     Global Antidiabetics Revenue and Market Share by Application (2014-2018)

6.2.1.  Global Antidiabetics Revenue and Revenue Share by Application (2014-2018)

6.3.     Type I Diabetes

6.3.1.  Global Type I Diabetes Revenue and Growth Rate (2014-2018)

6.4.     Type II Diabetes

6.4.1.  Global Type II Diabetes Revenue and Growth Rate (2014-2018)

7.       Antidiabetics Market, By Region

7.1.     Introduction

7.2.     Global Antidiabetics Revenue and Market Share by Regions

7.2.1.  Global Antidiabetics Revenue by Regions (2014-2018)

7.3.     North America Antidiabetics by Countries

7.3.1.  North America Antidiabetics Revenue and Growth Rate (2014-2018)

7.3.2.  North America Antidiabetics Revenue (Million USD) by Countries (2014-2018)

7.3.3.  United States

7.3.3.1.  United States Antidiabetics Revenue (Millions USD) and Growth Rate (2014-2018)

7.3.4.  Canada

7.3.4.1.  Canada Antidiabetics Revenue (Millions USD) and Growth Rate (2014-2018)

7.3.5.  Mexico

7.3.5.1.  Mexico Antidiabetics Revenue (Millions USD) and Growth Rate (2014-2018)

7.4.     Europe Antidiabetics by Countries

7.4.1.  Europe Antidiabetics Revenue and Growth Rate (2014-2018)

7.4.2.  Europe Antidiabetics Revenue (Million USD) by Countries (2014-2018)

7.4.3.  Germany

7.4.3.1.  Germany Antidiabetics Revenue (Millions USD) and Growth Rate (2014-2018)

7.4.4.  France

7.4.4.1.  France Antidiabetics Revenue (Millions USD) and Growth Rate (2014-2018)

7.4.5.  UK

7.4.5.1.  UK Antidiabetics Revenue (Millions USD) and Growth Rate (2014-2018)

7.4.6.  Russia

7.4.6.1.  Russia Antidiabetics Revenue (Millions USD) and Growth Rate (2014-2018)

7.4.7.  Italy

7.4.7.1.  Italy Antidiabetics Revenue (Millions USD) and Growth Rate (2014-2018)

7.4.8.  Rest of Europe

7.4.8.1.  Rest of Europe Antidiabetics Revenue (Millions USD) and Growth Rate (2014-2018)

7.5.     Asia-Pacific Antidiabetics by Countries

7.5.1.  Asia-Pacific Antidiabetics Revenue and Growth Rate (2014-2018)

7.5.2.  Asia-Pacific Antidiabetics Revenue (Million USD) by Countries (2014-2018)

7.5.3.  China

7.5.3.1.  China Antidiabetics Revenue (Millions USD) and Growth Rate (2014-2018)

7.5.4.  Japan

7.5.4.1.  Japan Antidiabetics Revenue (Millions USD) and Growth Rate (2014-2018)

7.5.5.  Korea

7.5.5.1.  Korea Antidiabetics Revenue (Millions USD) and Growth Rate (2014-2018)

7.5.6.  India

7.5.6.1.  India Antidiabetics Revenue (Millions USD) and Growth Rate (2014-2018)

7.5.7.  Southeast Asia

7.5.7.1.  Southeast Asia Antidiabetics Revenue (Millions USD) and Growth Rate (2014-2018)

7.5.8.  Rest of Asia-Pacific

7.5.8.1.  Rest of Asia-Pacific Antidiabetics Revenue (Millions USD) and Growth Rate (2014-2018)

7.6.     South America Antidiabetics by Countries

7.6.1.  South America Antidiabetics Revenue and Growth Rate (2014-2018)

7.6.2.  South America Antidiabetics Revenue (Million USD) by Countries (2014-2018)

7.6.3.  Brazil

7.6.3.1.  Brazil Antidiabetics Revenue (Millions USD) and Growth Rate (2014-2018)

7.6.4.  Argentina

7.6.4.1.  Argentina Antidiabetics Revenue (Millions USD) and Growth Rate (2014-2018)

7.6.5.  Columbia

7.6.5.1.  Columbia Antidiabetics Revenue (Millions USD) and Growth Rate (2014-2018)

7.6.6.  Rest of South America

7.6.6.1.  Rest of South America Antidiabetics Revenue (Millions USD) and Growth Rate (2014-2018)

7.7.     Middle East and Africa Antidiabetics by Countries

7.7.1.  Middle East and Africa Antidiabetics Revenue and Growth Rate (2014-2018)

7.7.2.  Middle East and Africa Antidiabetics Revenue (Million USD) by Countries (2014-2018)

7.7.3.  Saudi Arabia

7.7.3.1.  Saudi Arabia Antidiabetics Revenue (Millions USD) and Growth Rate (2014-2018)

7.7.4.  United Arab Emirates

7.7.4.1.  United Arab Emirates Antidiabetics Revenue (Millions USD) and Growth Rate (2014-2018)

7.7.5.  Egypt

7.7.5.1.  Egypt Antidiabetics Revenue (Millions USD) and Growth Rate (2014-2018)

7.7.6.  Nigeria

7.7.6.1.  Nigeria Antidiabetics Revenue (Millions USD) and Growth Rate (2014-2018)

7.7.7.  South Africa

7.7.7.1.  South Africa Antidiabetics Revenue (Millions USD) and Growth Rate (2014-2018)

7.7.8.  Turkey

7.7.8.1.  Turkey Antidiabetics Revenue (Millions USD) and Growth Rate (2014-2018)

7.7.9.  Rest of Middle East and Africa

7.7.9.1.  Rest of Middle East and Africa Antidiabetics Revenue (Millions USD) and Growth Rate (2014-2018)

8.       Company Profiles

8.1.     Takeda Pharmaceutical

8.1.1.  Business Overview

8.1.2.   Service Portfolio

8.1.3.  Strategic Developments

8.1.4.  Financial Overview

8.2.     Sanofi Aventis

8.2.1.  Business Overview

8.2.2.   Service Portfolio

8.2.3.  Strategic Developments

8.2.4.  Financial Overview

8.3.     Eli Lilly

8.3.1.  Business Overview

8.3.2.   Service Portfolio

8.3.3.  Strategic Developments

8.3.4.  Financial Overview

8.4.     Oramed Pharmaceuticals Inc.

8.4.1.  Business Overview

8.4.2.   Service Portfolio

8.4.3.  Strategic Developments

8.4.4.  Financial Overview

8.5.     Boehringer Ingelheim

8.5.1.  Business Overview

8.5.2.   Service Portfolio

8.5.3.  Strategic Developments

8.5.4.  Financial Overview

8.6.     Merck & Co. Inc

8.6.1.  Business Overview

8.6.2.   Service Portfolio

8.6.3.  Strategic Developments

8.6.4.  Financial Overview

8.7.     Bristol-Myers Squibb

8.7.1.  Business Overview

8.7.2.   Service Portfolio

8.7.3.  Strategic Developments

8.7.4.  Financial Overview

8.8.     Novo Nordisk

8.8.1.  Business Overview

8.8.2.   Service Portfolio

8.8.3.  Strategic Developments

8.8.4.  Financial Overview

8.9.     Pfizer

8.9.1.  Business Overview

8.9.2.   Service Portfolio

8.9.3.  Strategic Developments

8.9.4.  Financial Overview

8.10. Halozyme Therapeutics

8.10.1.      Business Overview

8.10.2.       Service Portfolio

8.10.3.      Strategic Developments

8.10.4.      Financial Overview

9.       Antidiabetics Market Forecast (2018-2025)

9.1.     Global Antidiabetics Revenue (Millions USD) and Growth Rate (2018-2025)

9.2.     Antidiabetics Market Forecast by Regions (2018-2025)

9.2.1.  North America Antidiabetics Market Forecast (2018-2025)

9.2.1.1.  United States Antidiabetics Market Forecast (2018-2025)

9.2.1.2.  Canada Antidiabetics Market Forecast (2018-2025)

9.2.1.3.  Mexico Antidiabetics Market Forecast (2018-2025)

9.2.2.  Europe Antidiabetics Market Forecast (2018-2025)

9.2.2.1.  Germany Antidiabetics Market Forecast (2018-2025)

9.2.2.2.  France Antidiabetics Market Forecast (2018-2025)

9.2.2.3.  UK Antidiabetics Market Forecast (2018-2025)

9.2.2.4.  Russia Antidiabetics Market Forecast (2018-2025)

9.2.2.5.  Italy Antidiabetics Market Forecast (2018-2025)

9.2.2.6.  Rest of Europe Antidiabetics Market Forecast (2018-2025)

9.2.3.  Asia-Pacific Antidiabetics Market Forecast (2018-2025)

9.2.3.1.  China Antidiabetics Market Forecast (2018-2025)

9.2.3.2.  Japan Antidiabetics Market Forecast (2018-2025)

9.2.3.3.  Korea Antidiabetics Market Forecast (2018-2025)

9.2.3.4.  India Antidiabetics Market Forecast (2018-2025)

9.2.3.5.  Southeast Asia Antidiabetics Market Forecast (2018-2025)

9.2.3.6.  Rest of Asia-Pacific Antidiabetics Market Forecast (2018-2025)

9.2.4.  South America Antidiabetics Market Forecast (2018-2025)

9.2.4.1.  Brazil Antidiabetics Market Forecast (2018-2025)

9.2.4.2.  Argentina Antidiabetics Market Forecast (2018-2025)

9.2.4.3.  Columbia Antidiabetics Market Forecast (2018-2025)

9.2.4.4.  Rest of South America Antidiabetics Market Forecast (2018-2025)

9.2.5.  Middle East and Africa Antidiabetics Market Forecast (2018-2025)

9.2.5.1.  Saudi Arabia Antidiabetics Market Forecast (2018-2025)

9.2.5.2.  United Arab Emirates Antidiabetics Market Forecast (2018-2025)

9.2.5.3.  Egypt Antidiabetics Market Forecast (2018-2025)

9.2.5.4.  Nigeria Antidiabetics Market Forecast (2018-2025)

9.2.5.5.  South Africa Antidiabetics Market Forecast (2018-2025)

9.2.5.6.  Turkey Antidiabetics Market Forecast (2018-2025)

9.2.5.7.  Rest of Middle East and Africa Antidiabetics Market Forecast (2018-2025)

9.3.     Antidiabetics Market Forecast by Product (2018-2025)

9.3.1.  Antidiabetics Forecast by Product (2018-2025)

9.3.2.  Antidiabetics Market Share Forecast by Product (2018-2025)

9.4.     Antidiabetics Market Forecast by Application (2018-2025)

9.4.1.  Antidiabetics Forecast by Application (2018-2025)

9.4.2.  Antidiabetics Market Share Forecast by Application (2018-2025)


List of Tables

Figure United States Antidiabetics Revenue (Million USD) and Growth Rate (2014-2025)
Figure Canada Antidiabetics Revenue (Million USD) and Growth Rate (2014-2025)
Figure Mexico Antidiabetics Revenue (Million USD) and Growth Rate (2014-2025)
Figure Germany Antidiabetics Revenue (Million USD) and Growth Rate (2014-2025)
Figure France Antidiabetics Revenue (Million USD) and Growth Rate (2014-2025)
Figure UK Antidiabetics Revenue (Million USD) and Growth Rate (2014-2025)
Figure Russia Antidiabetics Revenue (Million USD) and Growth Rate (2014-2025)
Figure Italy Antidiabetics Revenue (Million USD) and Growth Rate (2014-2025)
Figure Rest of Europe Antidiabetics Revenue (Million USD) and Growth Rate (2014-2025)
Figure China Antidiabetics Revenue (Million USD) and Growth Rate (2014-2025)
Figure Japan Antidiabetics Revenue (Million USD) and Growth Rate (2014-2025)
Figure Korea Antidiabetics Revenue (Million USD) and Growth Rate (2014-2025)
Figure India Antidiabetics Revenue (Million USD) and Growth Rate (2014-2025)
Figure Southeast Asia Antidiabetics Revenue (Million USD) and Growth Rate (2014-2025)
Figure Rest of Asia-Pacific Antidiabetics Revenue (Million USD) and Growth Rate (2014-2025)
Figure Brazil Antidiabetics Revenue (Million USD) and Growth Rate (2014-2025)
Figure Argentina Antidiabetics Revenue (Million USD) and Growth Rate (2014-2025)
Figure Columbia Antidiabetics Revenue (Million USD) and Growth Rate (2014-2025)
Figure Rest of South America Antidiabetics Revenue (Million USD) and Growth Rate (2014-2025)
Figure Saudi Arabia Antidiabetics Revenue (Million USD) and Growth Rate (2014-2025)
Figure United Arab Emirates Antidiabetics Revenue (Million USD) and Growth Rate (2014-2025)
Figure Egypt Antidiabetics Revenue (Million USD) and Growth Rate (2014-2025)
Figure Nigeria Antidiabetics Revenue (Million USD) and Growth Rate (2014-2025)
Figure South Africa Antidiabetics Revenue (Million USD) and Growth Rate (2014-2025)
Figure Turkey Antidiabetics Revenue (Million USD) and Growth Rate (2014-2025)
Figure Rest of Middle East and Africa Antidiabetics Revenue (Million USD) and Growth Rate (2014-2025)
Table Global Antidiabetics Revenue and Revenue Share by Product (2014-2018)
Figure Global Long Acting Revenue and Growth Rate (2014-2018)
Figure Global Premixed Insulin Revenue and Growth Rate (2014-2018)
Figure Global Intermediate Acting Revenue and Growth Rate (2014-2018)
Figure Global Rapid Acting Revenue and Growth Rate (2014-2018)
Figure Global Premixed Analog Revenue and Growth Rate (2014-2018)
Figure Global Other Products Revenue and Growth Rate (2014-2018)
Table Global Antidiabetics Revenue and Revenue Share by Application (2014-2018)
Figure Global Type I Diabetes Revenue and Growth Rate (2014-2018)
Figure Global Type II Diabetes Revenue and Growth Rate (2014-2018)
Table Global Antidiabetics Revenue by Regions (2014-2018)
Figure North America Antidiabetics Growth Rate (2014-2018)
Figure North America Antidiabetics Revenue and Growth Rate (2014-2018)
Figure North America Antidiabetics by Countries (2014-2018)
Figure North America Antidiabetics Revenue (Million USD) by Countries (2014-2018)
Figure United States Antidiabetics Growth Rate (2014-2018)
Figure United States Antidiabetics Revenue (Millions USD) and Growth Rate (2014-2018)
Figure Canada Antidiabetics Growth Rate (2014-2018)
Figure Canada Antidiabetics Revenue (Millions USD) and Growth Rate (2014-2018)
Figure Mexico Antidiabetics Growth Rate (2014-2018)
Figure Mexico Antidiabetics Revenue (Millions USD) and Growth Rate (2014-2018)
Figure Europe Antidiabetics Growth Rate (2014-2018)
Figure Europe Antidiabetics Revenue and Growth Rate (2014-2018)
Figure Europe Antidiabetics by Countries (2014-2018)
Figure Europe Antidiabetics Revenue (Million USD) by Countries (2014-2018)
Figure Germany Antidiabetics Growth Rate (2014-2018)
Figure Germany Antidiabetics Revenue (Millions USD) and Growth Rate (2014-2018)
Figure France Antidiabetics Growth Rate (2014-2018)
Figure France Antidiabetics Revenue (Millions USD) and Growth Rate (2014-2018)
Figure UK Antidiabetics Growth Rate (2014-2018)
Figure UK Antidiabetics Revenue (Millions USD) and Growth Rate (2014-2018)
Figure Russia Antidiabetics Growth Rate (2014-2018)
Figure Russia Antidiabetics Revenue (Millions USD) and Growth Rate (2014-2018)
Figure Italy Antidiabetics Growth Rate (2014-2018)
Figure Italy Antidiabetics Revenue (Millions USD) and Growth Rate (2014-2018)
Figure Rest of Europe Antidiabetics Growth Rate (2014-2018)
Figure Rest of Europe Antidiabetics Revenue (Millions USD) and Growth Rate (2014-2018)
Figure Asia-Pacific Antidiabetics Growth Rate (2014-2018)
Figure Asia-Pacific Antidiabetics Revenue and Growth Rate (2014-2018)
Figure Asia-Pacific Antidiabetics by Countries (2014-2018)
Figure Asia-Pacific Antidiabetics Revenue (Million USD) by Countries (2014-2018)
Figure China Antidiabetics Growth Rate (2014-2018)
Figure China Antidiabetics Revenue (Millions USD) and Growth Rate (2014-2018)
Figure Japan Antidiabetics Growth Rate (2014-2018)
Figure Japan Antidiabetics Revenue (Millions USD) and Growth Rate (2014-2018)
Figure Korea Antidiabetics Growth Rate (2014-2018)
Figure Korea Antidiabetics Revenue (Millions USD) and Growth Rate (2014-2018)
Figure India Antidiabetics Growth Rate (2014-2018)
Figure India Antidiabetics Revenue (Millions USD) and Growth Rate (2014-2018)
Figure Southeast Asia Antidiabetics Growth Rate (2014-2018)
Figure Southeast Asia Antidiabetics Revenue (Millions USD) and Growth Rate (2014-2018)
Figure Rest of Asia-Pacific Antidiabetics Growth Rate (2014-2018)
Figure Rest of Asia-Pacific Antidiabetics Revenue (Millions USD) and Growth Rate (2014-2018)
Figure South America Antidiabetics Growth Rate (2014-2018)
Figure South America Antidiabetics Revenue and Growth Rate (2014-2018)
Figure South America Antidiabetics by Countries (2014-2018)
Figure South America Antidiabetics Revenue (Million USD) by Countries (2014-2018)
Figure Brazil Antidiabetics Growth Rate (2014-2018)
Figure Brazil Antidiabetics Revenue (Millions USD) and Growth Rate (2014-2018)
Figure Argentina Antidiabetics Growth Rate (2014-2018)
Figure Argentina Antidiabetics Revenue (Millions USD) and Growth Rate (2014-2018)
Figure Columbia Antidiabetics Growth Rate (2014-2018)
Figure Columbia Antidiabetics Revenue (Millions USD) and Growth Rate (2014-2018)
Figure Rest of South America Antidiabetics Growth Rate (2014-2018)
Figure Rest of South America Antidiabetics Revenue (Millions USD) and Growth Rate (2014-2018)
Figure Middle East and Africa Antidiabetics Growth Rate (2014-2018)
Figure Middle East and Africa Antidiabetics Revenue and Growth Rate (2014-2018)
Figure Middle East and Africa Antidiabetics by Countries (2014-2018)
Figure Middle East and Africa Antidiabetics Revenue (Million USD) by Countries (2014-2018)
Figure Saudi Arabia Antidiabetics Growth Rate (2014-2018)
Figure Saudi Arabia Antidiabetics Revenue (Millions USD) and Growth Rate (2014-2018)
Figure United Arab Emirates Antidiabetics Growth Rate (2014-2018)
Figure United Arab Emirates Antidiabetics Revenue (Millions USD) and Growth Rate (2014-2018)
Figure Egypt Antidiabetics Growth Rate (2014-2018)
Figure Egypt Antidiabetics Revenue (Millions USD) and Growth Rate (2014-2018)
Figure Nigeria Antidiabetics Growth Rate (2014-2018)
Figure Nigeria Antidiabetics Revenue (Millions USD) and Growth Rate (2014-2018)
Figure South Africa Antidiabetics Growth Rate (2014-2018)
Figure South Africa Antidiabetics Revenue (Millions USD) and Growth Rate (2014-2018)
Figure Turkey Antidiabetics Growth Rate (2014-2018)
Figure Turkey Antidiabetics Revenue (Millions USD) and Growth Rate (2014-2018)
Figure Rest of Middle East and Africa Antidiabetics Growth Rate (2014-2018)
Figure Rest of Middle East and Africa Antidiabetics Revenue (Millions USD) and Growth Rate (2014-2018)
Table Takeda Pharmaceutical Antidiabetics Financial Overview
Table Sanofi Aventis Antidiabetics Financial Overview
Table Eli Lilly Antidiabetics Financial Overview
Table Oramed Pharmaceuticals Inc. Antidiabetics Financial Overview
Table Boehringer Ingelheim Antidiabetics Financial Overview
Table Merck & Co. Inc Antidiabetics Financial Overview
Table Bristol-Myers Squibb Antidiabetics Financial Overview
Table Novo Nordisk Antidiabetics Financial Overview
Table Pfizer Antidiabetics Financial Overview
Table Halozyme Therapeutics Antidiabetics Financial Overview
Figure Global Antidiabetics Revenue (Millions USD) and Growth Rate (2018-2025)
Table Antidiabetics Market Forecast by Regions (2018-2025)
Figure North America Antidiabetics Market Forecast (2018-2025)
Figure United States Antidiabetics Market Forecast (2018-2025)
Figure Canada Antidiabetics Market Forecast (2018-2025)
Figure Mexico Antidiabetics Market Forecast (2018-2025)
Figure Europe Antidiabetics Market Forecast (2018-2025)
Figure Germany Antidiabetics Market Forecast (2018-2025)
Figure France Antidiabetics Market Forecast (2018-2025)
Figure UK Antidiabetics Market Forecast (2018-2025)
Figure Russia Antidiabetics Market Forecast (2018-2025)
Figure Italy Antidiabetics Market Forecast (2018-2025)
Figure Rest of Europe Antidiabetics Market Forecast (2018-2025)
Figure Asia-Pacific Antidiabetics Market Forecast (2018-2025)
Figure China Antidiabetics Market Forecast (2018-2025)
Figure Japan Antidiabetics Market Forecast (2018-2025)
Figure Korea Antidiabetics Market Forecast (2018-2025)
Figure India Antidiabetics Market Forecast (2018-2025)
Figure Southeast Asia Antidiabetics Market Forecast (2018-2025)
Figure Rest of Asia-Pacific Antidiabetics Market Forecast (2018-2025)
Figure South America Antidiabetics Market Forecast (2018-2025)
Figure Brazil Antidiabetics Market Forecast (2018-2025)
Figure Argentina Antidiabetics Market Forecast (2018-2025)
Figure Columbia Antidiabetics Market Forecast (2018-2025)
Figure Rest of South America Antidiabetics Market Forecast (2018-2025)
Figure Middle East and Africa Antidiabetics Market Forecast (2018-2025)
Figure Saudi Arabia Antidiabetics Market Forecast (2018-2025)
Figure United Arab Emirates Antidiabetics Market Forecast (2018-2025)
Figure Egypt Antidiabetics Market Forecast (2018-2025)
Figure Nigeria Antidiabetics Market Forecast (2018-2025)
Figure South Africa Antidiabetics Market Forecast (2018-2025)
Figure Turkey Antidiabetics Market Forecast (2018-2025)
Figure Rest of Middle East and Africa Antidiabetics Market Forecast (2018-2025)
Figure Global Antidiabetics Forecast by Product (2018-2025)
Figure Global Antidiabetics Market Share Forecast by Product (2018-2025)
Figure Global Antidiabetics Forecast by Product (2018-2025)
Figure Global Antidiabetics Forecast by Application (2018-2025)
Figure Global Antidiabetics Market Share Forecast by Application (2018-2025)
Figure Global Antidiabetics Forecast by Application (2018-2025)

Please Note: Data related to the Companies are subject to Availability.


Research Methodology

We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.

Data Mining

Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.

Data Collection Matrix

Data Collection Matrix

Supply Side

Demand Side

Primary Data Sources

  • Manufacturers
  • Distributors & Wholesalers
  • GPOs
  • Physicians/Specialist
  • Healthcare Providers
  • Consumers

Secondary Data Sources

  • Annual Reports/SEC Filings/ Investor Presentations/ Press Releases
  • Government/Associations Publications
  • Case Studies
  • Reference Customers

 

Market Modeling and Forecasting

We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.

  • Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
  • Number of patients for particular device or medical procedure and
  • Repeated use of particular device depending on health and condition of patient
  • Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.

We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.

Data Validation

We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.

Data Triangulation

data triangulation

Industry Analysis

Qualitative Data

Quantitative Data (2017-2025)

  • Market Dynamics (Drivers, Restraints, and Challenges)
  • Industry Trend Analysis
  • Market Opportunities
  • Government Policies and Regulations, Patent Analysis, and Reimbursement Policies
  • Porter’s Five Forces and PESTLE Analysis
  • Key Developments and Competitive Landscape
  • Market Assessment and Forecast
  • Market Assessment and Forecast, By Product
  • Market Assessment and Forecast, By Technology
  • Market Assessment and Forecast, By Application
  • Market Assessment and Forecast, By End User
  • Market Assessment and Forecast, By Region/Country

License Type

For Any Assistance

*
*
*
*
*